3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Sarcoma
3
CNS
3
Conditions
Gliosarcoma
3
Glioblastoma
3
Neoplasms
2
Glioma
2
Brain Neoplasms
2
Recurrence
1
Interventions
Temozolomide
93
Radiotherapy
66
Bevacizumab
35
Radiation
22
Carmustine
21
Erlotinib Hydrochloride
17
Chemotherapy, Adjuvant
17
Irinotecan
16
Magnetic Resonance Spectroscopy
13
Radiotherapy, Conformal
11
O(6)-benzylguanine
11
Surgical Procedures, Operative
10
Radiotherapy, Intensity-Modulated
10
sargramostim
9
Sirolimus
9
Imatinib Mesylate
9
Carboplatin
9
temsirolimus
8
motexafin gadolinium
7
Thalidomide
7
Gene Expression Profiling
7
aldesleukin
6
Sorafenib
6
Radiosurgery
6
Immunohistochemistry
6
Hydroxyurea
6
Gefitinib
6
Filgrastim
6
Everolimus
6
Etoposide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Gliosarcoma
×
rindopepimut
×
Clear all
NCT01498328
2020-02-17
ReACT
Celldex Therapeutics
Phase 2
Completed
127 enrolled
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled
NCT00626015
2016-01-21
ZAP IT
Duke University
Phase 1
Completed
16 enrolled